Progression-free survival following primary staging with [¹⁸F]PSMA-1007-PET/ceCT versus Na[¹⁸F]F-PET/ceCT in prostate cancer: Results from the PRISMA-PET randomized controlled trial

Presse/medie

Beskrivelse

Interview under EAU26 efter præsentation af resultater fra PRISMA-PET

prostatakræft

stadieinddeling

PSMA-PET/CT

patient benefit

Periode	15. mar. 2026

Titel	Progression-free survival following primary staging with [¹⁸F]PSMA-1007-PET/ceCT versus Na[¹⁸F]F-PET/ceCT in prostate cancer: Results from the PRISMA-PET randomized controlled trial
Mediets navn/udløb	medical digest congress report
Medietype	Internet
Land/Område	Danmark
Dato	15/03/2026
Beskrivelse	Interview under EAU26 efter præsentation af resultater fra PRISMA-PET
Personer	Karen Middelbo Buch-Olsen